Ani Pharmaceuticals Stock Performance
| ANIP Stock | USD 65.48 0.08 0.12% |
On a scale of 0 to 100, ANI Pharmaceuticals holds a performance score of 10. The firm shows a Beta (market volatility) of 0.83, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, ANI Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding ANI Pharmaceuticals is expected to be smaller as well. Please check ANI Pharmaceuticals' potential upside, and the relationship between the total risk alpha and kurtosis , to make a quick decision on whether ANI Pharmaceuticals' price patterns will revert.
Risk-Adjusted Performance
10 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in ANI Pharmaceuticals are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak forward indicators, ANI Pharmaceuticals reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (1.12) | Five Day Return (3.29) | Year To Date Return 14.64 | Ten Year Return 156.59 | All Time Return (69.33) |
Last Split Factor 1:6 | Last Split Date 2013-07-18 |
1 | Disposition of 1261 shares by Christopher Mutz of ANI Pharmaceuticals at 57.55 subject to Rule 16b-3 | 02/15/2024 |
2 | Acquisition by Shanmugam Muthusamy of 13421 shares of ANI Pharmaceuticals subject to Rule 16b-3 | 02/16/2024 |
3 | Wall Street Analysts See ANI as a Buy Should You Invest | 03/01/2024 |
4 | Why Moderna Stock Price Was Up 9 percent on Monday | 03/12/2024 |
5 | Disposition of 17455 shares by Nikhil Lalwani of ANI Pharmaceuticals at 69.58 subject to Rule 16b-3 | 03/22/2024 |
6 | Disposition of 3653 shares by James Marken of ANI Pharmaceuticals at 69.58 subject to Rule 16b-3 | 03/28/2024 |
7 | ANI Pharmaceuticals Dips More Than Broader Market What You Should Know | 04/02/2024 |
8 | EMA Accepts Rocket Gene Therapy Filing for Fanconi Anemia | 04/03/2024 |
9 | Amarin Up 7 percent on Intellectual Property Wins in Europe | 04/04/2024 |
10 | Wall Street Analysts Think ANI Is a Good Investment Is It | 04/05/2024 |
11 | ANI Pharmaceuticals Announces the Launch of Baclofen Oral Suspension | 04/09/2024 |
12 | ANI Pharmaceuticals Stock Moves -0.13 percent What You Should Know | 04/10/2024 |
13 | With 64 percent ownership of the shares, ANI Pharmaceuticals, Inc. is heavily dominated by institutional owners | 04/12/2024 |
14 | Aptevo Stock Plummets 79 percent in a Week Heres Why | 04/16/2024 |
| Begin Period Cash Flow | 53.2 M |
ANI |
ANI Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 5,559 in ANI Pharmaceuticals on January 18, 2024 and sell it today you would earn a total of 997.00 from holding ANI Pharmaceuticals or generate 17.93% return on investment over 90 days. ANI Pharmaceuticals is currently generating 0.283% in daily expected returns and assumes 2.0976% risk (volatility on return distribution) over the 90 days horizon. In different words, 18% of stocks are less volatile than ANI, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
ANI Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ANI Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ANI Pharmaceuticals, and traders can use it to determine the average amount a ANI Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1349
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ANIP | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.1 actual daily | 18 82% of assets are more volatile |
Expected Return
| 0.28 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.13 actual daily | 10 90% of assets perform better |
Based on monthly moving average ANI Pharmaceuticals is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ANI Pharmaceuticals by adding it to a well-diversified portfolio.
ANI Pharmaceuticals Fundamentals Growth
ANI Stock prices reflect investors' perceptions of the future prospects and financial health of ANI Pharmaceuticals, and ANI Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ANI Stock performance.
| Return On Equity | 0.0472 | ||||
| Return On Asset | 0.0372 | ||||
| Profit Margin | 0.04 % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 1.4 B | ||||
| Shares Outstanding | 20.98 M | ||||
| Price To Earning | 43.35 X | ||||
| Price To Book | 3.24 X | ||||
| Price To Sales | 2.88 X | ||||
| Revenue | 486.82 M | ||||
| Gross Profit | 177.6 M | ||||
| EBITDA | 109.32 M | ||||
| Net Income | 18.78 M | ||||
| Cash And Equivalents | 63.38 M | ||||
| Cash Per Share | 3.89 X | ||||
| Total Debt | 315.33 M | ||||
| Debt To Equity | 0.85 % | ||||
| Current Ratio | 3.35 X | ||||
| Book Value Per Share | 22.64 X | ||||
| Cash Flow From Operations | 118.96 M | ||||
| Earnings Per Share | 0.85 X | ||||
| Market Capitalization | 1.39 B | ||||
| Total Asset | 904.42 M | ||||
| Retained Earnings | (80.13 M) | ||||
| Working Capital | 374.34 M | ||||
| Current Asset | 192.58 M | ||||
| Current Liabilities | 11.76 M | ||||
About ANI Pharmaceuticals Performance
To evaluate ANI Pharmaceuticals Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when ANI Pharmaceuticals generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare ANI Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand ANI Pharmaceuticals market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents ANI's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 168.20 | 189.10 | |
| Return On Tangible Assets | 0.03 | 0.03 | |
| Return On Capital Employed | 0.07 | 0.07 | |
| Return On Assets | 0.02 | 0.02 | |
| Return On Equity | 0.04 | 0.05 |
Things to note about ANI Pharmaceuticals performance evaluation
Checking the ongoing alerts about ANI Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ANI Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ANI Pharmaceuticals is unlikely to experience financial distress in the next 2 years | |
| ANI Pharmaceuticals has a strong financial position based on the latest SEC filings | |
| Over 76.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Aptevo Stock Plummets 79 percent in a Week Heres Why |
- Analyzing ANI Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ANI Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining ANI Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ANI Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of ANI Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ANI Pharmaceuticals' stock. These opinions can provide insight into ANI Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ANI Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Complementary Tools for ANI Stock analysis
When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |
Is ANI Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ANI Pharmaceuticals. If investors know ANI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ANI Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.89) | Earnings Share 0.85 | Revenue Per Share 27.044 | Quarterly Revenue Growth 0.397 | Return On Assets 0.0372 |
The market value of ANI Pharmaceuticals is measured differently than its book value, which is the value of ANI that is recorded on the company's balance sheet. Investors also form their own opinion of ANI Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ANI Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ANI Pharmaceuticals' market value can be influenced by many factors that don't directly affect ANI Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ANI Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ANI Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ANI Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.